{"id":762941,"date":"2023-06-12T08:03:40","date_gmt":"2023-06-12T12:03:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/"},"modified":"2023-06-12T08:03:40","modified_gmt":"2023-06-12T12:03:40","slug":"revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/","title":{"rendered":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Signals Research Suite integrates workflows across biology, chemistry and materials new product development to arm scientists with better data, insights and outcomes<\/i><\/li>\n<li><i>Centrally installed and managed, the integrated suite covers the entire Make-Test-Decide lifecycle<\/i><\/li>\n<li><i>First solution released by Revvity under the new Revvity Signals Software brand<\/i><\/li>\n<\/ul>\n<p>WALTHAM, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nToday, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2F&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Revvity%2C+Inc.&amp;index=1&amp;md5=b14dc877e34e30a3aac353af9cb7b6bb\">Revvity, Inc.<\/a> (NYSE: RVTY), announced the launch of its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2Fproducts%2Fresearch%2Fsignals-research-suite&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Signals+Research+Suite&amp;index=2&amp;md5=a6378b53b3d1d64a20ff6446ec5f0514\">Signals Research Suite<\/a>, a unified, cloud-native SaaS platform that drives scientific collaboration across R&amp;D disciplines from drug discovery to specialty chemicals material development. The new solution from <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2F%3Fgclid%3DCj0KCQjw4NujBhC5ARIsAF4Iv6c2MO3tEohnXhuFHVZiM7qEX5ryhdIgIbf-eDMLO7jo9rqxGwCLSrAaAnLJEALw_wcB&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Revvity+Signals+Software&amp;index=3&amp;md5=bef7c596811be7000b7535a444986a44\">Revvity Signals Software<\/a>, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2Fproducts%2Fresearch%2Fsignals-notebook-eln&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Signals+Notebook&amp;index=4&amp;md5=0d5c6584dbda4189ae25f8f787e1bb8e\">Signals Notebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2Fproducts%2Fresearch%2Fsignals-vitrovivo&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=VitroVivo&amp;index=5&amp;md5=662f1f63c03a09a1615f9937fa894226\">VitroVivo<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fperkinelmerinformatics.com%2Fproducts%2Fresearch%2Fsignals-inventa&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Inventa&amp;index=6&amp;md5=6cd0a37bf40ea4dbbb4dd7dc8d36d154\">Inventa<\/a> applications into a single, robust solution that supports the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.<\/p>\n<p>\n\u201cWith the Signals Research Suite, scientists can go further in their work with one solution that encapsulates the products they already trust and avoids the complexities and inefficiencies of a piecemeal, application-centric ecosystem,\u201d said Kevin Willoe, senior vice president and general manager of the newly-branded Revvity Signals Software.<\/p>\n<p><b>A Unified Platform to Streamline Collaboration<br \/>\n<br \/><\/b>Unlike siloed point solutions that prevent seamless collaboration and data sharing, the Signals Research Suite includes a trio of scientifically intelligent and integrated software applications that serve the entire Make-Test-Decide lifecycle. It features advanced analytics, visualizations powered by TIBCO Spotfire<sup>\u00ae<\/sup>, native industry gold standard ChemDraw<sup>\u00ae<\/sup> integration, and a modern, streamlined interface that allows for complete control in configuring workflows for a wide-range of technique, modality and datatype interfaces. With secure single-sign-on access to all applications, as well as centrally located data tutorials, training videos and software release information, Signals Research Suite users can spend more time focusing on their experiments instead of switching between independent solutions.<\/p>\n<p><b>Secure Data that Supports Regulatory Compliance<br \/>\n<br \/><\/b>Developed in line with best practices for data security and integrity, the Signals Research Suite implements 24\/7 global security monitoring, alerting and escalation by the Revvity Signals Software Security Operations Center. The platform can be deployed in either a multi-tenant or private-cloud environment and is designed to meet standard IT requirements for automatic updates and cloud security controls. Also, by automating routine tasks and workflows, data within the Suite is findable, accessible, interoperable and reproducible (FAIR), aiding in data integrity and regulatory compliance.<\/p>\n<p><b>Better Data, Insights &amp; Outcomes<br \/>\n<br \/><\/b>The Signals Research Suite is the first fully integrated SaaS platform for both discovery chemistry and discovery biology, ideally suited for research use cases involving early and late stage in-vitro assays, cell line optimization, biologics process optimization, in vitro DMPK assays, animal pharmacokinetic studies, stage animal efficacy and safety studies. And, for the specialty chemicals industry, Signals Research Suite empowers new product development workflows by increasing productivity, helps to improve product performance by simplifying screening and optimization processes, reduces new product development timelines, and supports better decision making with easier data sharing. It is also the first solution <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.revvity.com%2Fpress-announcements%2Fpress-releases%2Fpress-release-details%2F2023%2FLaunching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure%2Fdefault.aspx&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=announced&amp;index=7&amp;md5=67252b10e1167a77d3257e59c11881bc\">announced<\/a> by the Revvity Signals Software brand since rebranding from PerkinElmer Informatics.<\/p>\n<p>\n\u201cAs a group, our commitment has long been to facilitate faster, more efficient communication between scientists by providing the tools they need to identify critical insights in data, share ideas and find information with ease,\u201d added Willoe. \u201cWe feel that the name \u2018Signals\u2019 embodies this commitment and will continue to guide our work into the future.\u201d<\/p>\n<p><b>About Revvity<br \/>\n<br \/><\/b>At Revvity, \u201cimpossible\u201d is inspiration, and \u201ccan\u2019t be done\u201d is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what\u2019s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.<\/p>\n<p>\nWith 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&amp;P 500 index and has customers in more than 190 countries.<\/p>\n<p>\nStay updated by following our <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.revvity.com&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Newsroom&amp;index=8&amp;md5=754dfd30448ba194d72530711deccc58\">Newsroom<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Frevvity%2F&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=0f4fa81cc057f3d6098556e65a6289fd\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FRevvityInc&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Twitter&amp;index=10&amp;md5=5b0a710ad705dc3edd9c0f7a2a9bd481\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCUqLrqOpUUwhz3UaLn78tVQ&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=73a795103b71c31116a8351776bc7836\">YouTube<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FRevvityInc&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Facebook&amp;index=12&amp;md5=026988c638ad8eefc0b0f11a6b99f04b\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Frevvity%2F&amp;esheet=53417777&amp;newsitemid=20230612005057&amp;lan=en-US&amp;anchor=Instagram&amp;index=13&amp;md5=714bf974ce823b5869a81b1e3784b7b4\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230612005057\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230612005057\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations:<br \/>\n<\/b><br \/>Steve Willoughby<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:steve.willoughby@revvity.com\">steve.willoughby@revvity.com<\/a><\/p>\n<p><b>Media Relations:<br \/>\n<\/b><br \/>Chet Murray<br \/>\n<br \/>(781) 462-5126<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:chet.murray@revvity.com\">chet.murray@revvity.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Chemicals\/Plastics Security Data Management Manufacturing Technology Pharmaceutical Professional Services Medical Devices Science Biotechnology Software Networks Data Analytics Other Science Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230612005057\/en\/1815388\/3\/rev_logo_rgb_black_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Signals Research Suite integrates workflows across biology, chemistry and materials new product development to arm scientists with better data, insights and outcomes Centrally installed and managed, the integrated suite covers the entire Make-Test-Decide lifecycle First solution released by Revvity under the new Revvity Signals Software brand WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Today, Revvity, Inc. (NYSE: RVTY), announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&amp;D disciplines from drug discovery to specialty chemicals material development. The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762941","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Signals Research Suite integrates workflows across biology, chemistry and materials new product development to arm scientists with better data, insights and outcomes Centrally installed and managed, the integrated suite covers the entire Make-Test-Decide lifecycle First solution released by Revvity under the new Revvity Signals Software brand WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Today, Revvity, Inc. (NYSE: RVTY), announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&amp;D disciplines from drug discovery to specialty chemicals material development. The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa &hellip; Continue reading &quot;Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T12:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development\",\"datePublished\":\"2023-06-12T12:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/\",\"name\":\"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-06-12T12:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/","og_locale":"en_US","og_type":"article","og_title":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk","og_description":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Signals Research Suite integrates workflows across biology, chemistry and materials new product development to arm scientists with better data, insights and outcomes Centrally installed and managed, the integrated suite covers the entire Make-Test-Decide lifecycle First solution released by Revvity under the new Revvity Signals Software brand WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211; Today, Revvity, Inc. (NYSE: RVTY), announced the launch of its Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across R&amp;D disciplines from drug discovery to specialty chemicals material development. The new solution from Revvity Signals Software, the software and informatics arm of Revvity, is available worldwide. It integrates the Revvity Signals Notebook, VitroVivo and Inventa &hellip; Continue reading \"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-12T12:03:40+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development","datePublished":"2023-06-12T12:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/","name":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-06-12T12:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230612005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-launches-first-scientific-saas-platform-to-accelerate-drug-and-materials-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762941"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762941\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}